An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics to Present Research at International Stroke Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics (NASDAQ: DMAC) will present two abstracts at the American Heart Association 2022 International Stroke Conference in New Orleans from February 9-11, 2022. The abstracts focus on:
Stroke Recurrence and Mortality with Recombinant Tissue Kallikrein Protein in the Remedy1 Phase 2 Trial
Randomized, Double-blind, Placebo-controlled Study to Evaluate DM199 for Acute Ischemic Stroke (ReMEDy2 Trial)
Presentations will occur on February 10, 2022, from 12:30 PM to 1:15 PM at Poster Hall B2. Visit DiaMedica's website for more details.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/international-stroke-conference.
The DiaMedica abstracts include:
Abstract Title: “Stroke Recurrence And Mortality With Recombinant Tissue Kallikrein Protein In The Remedy1 Phase 2 Trial”
Abstract Title: “Randomized, Double-blind, Placebo-controlled, Adaptive Design Study To Evaluate Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)”
These abstracts will be presented in person at Poster Hall B2 (Poster Boards CTP16 & CTP17) on Thursday February 10, 2022, from 12:30 PM – 01:15 PM. DiaMedica will also be exhibiting at the conference located in the main hall at booth 111.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.
What is DiaMedica Therapeutics presenting at the American Heart Association 2022 International Stroke Conference?
DiaMedica Therapeutics is presenting two abstracts focusing on stroke recurrence and the treatment of acute ischemic stroke with DM199.
When will DiaMedica's presentations take place at the conference?
The presentations will occur on February 10, 2022, from 12:30 PM to 1:15 PM.
Where can I find more information about DiaMedica's abstracts?
More information will be available on DiaMedica's website after the conference.
What are the titles of the abstracts presented by DiaMedica?
The abstracts are titled: 'Stroke Recurrence and Mortality with Recombinant Tissue Kallikrein Protein in the Remedy1 Phase 2 Trial' and 'Randomized, Double-blind, Placebo-controlled Study to Evaluate DM199 for Acute Ischemic Stroke (ReMEDy2 Trial)'.
What is the significance of DM199 for DiaMedica Therapeutics?
DM199 is DiaMedica's lead candidate and represents an innovative treatment for acute ischemic stroke and chronic kidney disease.
